USC.edu
Are You a Patient?

Mohamed Abou-el-Enein

Associate Professor of Medicine (Clinical Scholar), Pediatrics, and Stem Cell Biology & Regenerative Medicine

Executive Director, Joint USC/CHLA Cell Therapy Program

Image of Mohamed Abou-el-Enein
Is this your profile? Click to edit
Email mabouele@usc.edu
Orcid ID CTSI Profile

Publications

  • The Fate(s) of CAR T-Cell Therapy: Navigating the Risks of CAR+ T-Cell Malignancy Blood Cancer Discov. 2024 Jul 01; 5(4):249-257. . View in PubMed
  • Blood. 2024 Jun 20; 143(25):2599-2611. . View in PubMed
  • Disseminating transformative gene and cell therapy research Mol Ther Methods Clin Dev. 2024 Jun 13; 32(2):101246. . View in PubMed
  • Biomanufacturing in gene and cell therapy Mol Ther Methods Clin Dev. 2024 Jun 13; 32(2):101261. . View in PubMed
  • Cost-effectiveness of second-line lisocabtagene maraleucel in relapsed or refractory diffuse large B-cell lymphoma Blood Adv. 2024 Jan 23; 8(2):484-496. . View in PubMed
  • Bringing base editing to the clinic: The next generation of genome editors Mol Ther Methods Clin Dev. 2023 Dec 14; 31:101138. . View in PubMed
  • bioRxiv. 2023 Nov 14. . View in PubMed
  • Advancing in vivo genome editing: B cell engineering via adenoviral delivery systems Mol Ther. 2023 Sep 06; 31(9):2554-2556. . View in PubMed
  • CAR NK-92 cell-mediated depletion of residual TCR+ cells for ultrapure allogeneic TCR-deleted CAR T-cell products Blood Adv. 2023 Aug 08; 7(15):4124-4134. . View in PubMed
  • Non-viral chimeric antigen receptor (CAR) T cells going viral Immunooncol Technol. 2023 Jun; 18:100375. . View in PubMed
  • Long-term response to autologous anti-CD19 chimeric antigen receptor T cells in relapsed or refractory B cell acute lymphoblastic leukemia: a systematic review and meta-analysis Cancer Gene Ther. 2023 06; 30(6):845-854. . View in PubMed
  • Overcoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumours Nat Rev Clin Oncol. 2023 Jan; 20(1):49-62. . View in PubMed
  • Preparing for CAR T cell therapy: patient selection, bridging therapies and lymphodepletion Nat Rev Clin Oncol. 2022 05; 19(5):342-355. . View in PubMed
  • Cost-effectiveness of Axicabtagene Ciloleucel and Tisagenlecleucel as Second-line or Later Therapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma JAMA Netw Open. 2022 12 01; 5(12):e2245956. . View in PubMed
  • Adoptive transfer of ex vivo expanded regulatory T cells improves immune cell engraftment and therapy-refractory chronic GvHD Mol Ther. 2022 06 01; 30(6):2298-2314. . View in PubMed
  • The Value of CAR-T-cell Immunotherapy in Cancer The EBMT/EHA CAR-T Cell Handbook. 2022. . View in PubMed
  • Evidence generation and reproducibility in cell and gene therapy research: A call to action Mol Ther Methods Clin Dev. 2021 Sep 10; 22:11-14. . View in PubMed
  • Scalable Manufacturing of CAR T cells for Cancer Immunotherapy Blood Cancer Discov. 2021 Sep; 2(5):408-422. . View in PubMed
  • Detection of SARS-CoV-2-specific memory B cells to delineate long-term COVID-19 immunity Allergy. 2021 08; 76(8):2595-2599. . View in PubMed
  • Immunogenicity of CAR T cells in cancer therapy Nat Rev Clin Oncol. 2021 06; 18(6):379-393. . View in PubMed
  • Unproven stem cell interventions: A global public health problem requiring global deliberation Stem Cell Reports. 2021 06 08; 16(6):1435-1445. . View in PubMed
  • Mitigating Deficiencies in Evidence during Regulatory Assessments of Advanced Therapies: A Comparative Study with Other Biologicals Mol Ther Methods Clin Dev. 2020 Sep 11; 18:269-279. . View in PubMed
  • Toward an Optimized Process for Clinical Manufacturing of CAR-Treg Cell Therapy Trends Biotechnol. 2020 10; 38(10):1099-1112. . View in PubMed
  • CAR T-cell product performance in haematological malignancies before and after marketing authorisation Lancet Oncol. 2020 02; 21(2):e104-e116. . View in PubMed
  • Regulatory T cells for minimising immune suppression in kidney transplantation: phase I/IIa clinical trial BMJ. 2020 10 21; 371:m3734. . View in PubMed
  • COVID-19-Induced ARDS Is Associated with Decreased Frequency of Activated Memory/Effector T Cells Expressing CD11a+ Mol Ther. 2020 12 02; 28(12):2691-2702. . View in PubMed
  • Senolytic CAR T Cells in Solid Tumors and Age-Related Pathologies Mol Ther. 2020 10 07; 28(10):2108-2110. . View in PubMed
  • The Human Genome Editing Race: Loosening Regulatory Standards for Commercial Advantage? Trends Biotechnol. 2019 02; 37(2):120-123.. View in PubMed
  • Linking Scattered Stem Cell-Based Data to Advance Therapeutic Development Trends Mol Med. 2019 01; 25(1):8-19. . View in PubMed
  • Cell and Gene Therapy Trials: Are We Facing an ‘Evidence Crisis’? EClinicalMedicine. 2019 Jan; 7:13-14.. View in PubMed
  • Enhancing patient-level clinical data access to promote evidence-based practice and incentivize therapeutic innovation Adv Drug Deliv Rev. 2018 Nov – Dec; 136-137:97-104. . View in PubMed
  • Telbivudine in chronic lymphocytic myocarditis and human parvovirus B19 transcriptional activity ESC Heart Fail. 2018 10; 5(5):818-829. . View in PubMed
  • Concise Review: A Comprehensive Analysis of Reported Adverse Events in Patients Receiving Unproven Stem Cell-Based Interventions Stem Cells Transl Med. 2018 09; 7(9):676-685. . View in PubMed
  • Registry Contributions to Strengthen Cell and Gene Therapeutic Evidence Mol Ther. 2018 05 02; 26(5):1172-1176. . View in PubMed
  • Accelerating Patients’ Access to Advanced Therapies in the EU Mol Ther Methods Clin Dev. 2017 Dec 15; 7:15-19. . View in PubMed
  • Strategies for Derisking Translational Processes for Biomedical Technologies Trends Biotechnol. 2017 02; 35(2):100-108. . View in PubMed
  • The path to successful commercialization of cell and gene therapies: empowering patient advocates Cytotherapy. 2017 02; 19(2):293-298. . View in PubMed
  • Clinical Development of Cell Therapies: Setting the Stage for Academic Success Clin Pharmacol Ther. 2017 Jan; 101(1):35-38. . View in PubMed
  • Human Genome Editing in the Clinic: New Challenges in Regulatory Benefit-Risk Assessment Cell Stem Cell. 2017 10 05; 21(4):427-430. . View in PubMed
  • Deciphering the EU clinical trials regulation Nat Biotechnol. 2016 Mar; 34(3):231-3. . View in PubMed
  • Putting a price tag on novel autologous cellular therapies Cytotherapy. 2016 08; 18(8):1056-1061. . View in PubMed
  • Overcoming Challenges Facing Advanced Therapies in the EU Market Cell Stem Cell. 2016 09 01; 19(3):293-7. . View in PubMed
  • Gene therapy: a possible future standard for HIV care Trends Biotechnol. 2015 Jul; 33(7):374-6. . View in PubMed
  • The business case for cell and gene therapies Nat Biotechnol. 2014 Dec; 32(12):1192-3. . View in PubMed
  • A roadmap toward clinical translation of genetically-modified stem cells for treatment of HIV Trends Mol Med. 2014 Nov; 20(11):632-42. . View in PubMed
  • Good Manufacturing Practices (GMP) manufacturing of advanced therapy medicinal products: a novel tailored model for optimizing performance and estimating costs Cytotherapy. 2013 Mar; 15(3):362-83. . View in PubMed

Similar People